{"slideshow_credits": null, "snippet": "The Biotechnology Industry Organization cites differences between conventional generic drugs and biosimilars.", "abstract": null, "section_name": "Opinion", "print_page": "22", "document_type": "article", "byline": [], "web_url": "http://www.nytimes.com/2013/02/05/opinion/generics-and-patient-safety.html", "lead_paragraph": "The Biotechnology Industry Organization cites differences between conventional generic drugs and biosimilars.", "headline": {"main": "Generics and Patient Safety", "print_headline": "Generics and Patient Safety", "content_kicker": "Letter", "kicker": "Letter"}, "_id": "5110777400315214fbb89267", "word_count": "161", "multimedia": [], "pub_date": "2013-02-05T00:00:00Z", "source": "The New York Times", "news_desk": "Letters", "keywords": [{"value": "Drugs (Pharmaceuticals)", "name": "subject", "is_major": "N", "rank": "1"}, {"value": "Generic Brands and Products", "name": "subject", "is_major": "N", "rank": "2"}], "blog": [], "subsection_name": null, "type_of_material": "Letter"}